CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies

Jennifer Sun, Yixuan Chen, Berit Lubben, Ola Adebayo, Barbara Muz, Abdel Kareem Azab

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


CD47 is a surface glycoprotein expressed by host cells to impede phagocytosis upon binding to macrophage SIRPα, thereby represents an immune checkpoint known as the “don't-eat-me” signal. However, accumulating evidence shows that solid and hematologic tumor cells overexpress CD47 to escape immune surveillance. Thus, targeting the CD47-SIRPa axis by limiting the activity of this checkpoint has emerged as a key area of research. In this review, we will provide an update on the landscape of CD47-targeting antibodies for hematological malignancies, including monoclonal and bi-specific antibodies, with a special emphasis on agents in clinical trials and novel approaches to overcome toxicity.

Original languageEnglish
Article number100268
JournalLeukemia Research Reports
StatePublished - Jan 2021


  • CD47
  • Checkpoint inhibition
  • Hematologic malignancies
  • Immunotherapy
  • Macrophage


Dive into the research topics of 'CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies'. Together they form a unique fingerprint.

Cite this